HomeHealthMedicineInsilico Medicine Awarded Over $700,000 to Design New

Insilico Medicine Awarded Over $700,000 to Design New

New York, Nov. 23, 2022 (GLOBE NEWSWIRE) — Insilico Medicine, a clinical-stage, end-to-end artificial intelligence (AI)-powered drug discovery company, is designing new non-hormonal contraceptive options for women using its AI platform with support from a grant of more than $700,000 from the Bill & Melinda Gates Foundation.

Petrina Kamya, PhD, head of AI platforms at Insilico Medicine, participated in the Foundation’s Fall 2022 Non-Hormonal Contraception Annual Meeting and Grand Challenges, October 22-27 in Brussels.

“We are thrilled to have the opportunity to use our AI drug discovery and design platform to help design new contraceptive options for women around the world, which represents a great unmet need,” said Dr. Kamya.

Using its Pharma.AI platform, Insilico will develop completely new small molecules to further interrogate and evaluate targets potentially leading to a contraceptive effect. The platform optimizes molecules with desirable properties such as potency, synthetic accessibility, specificity and metabolic stability to have the greatest chance of success.

More than 200 million women and girls in low- and middle-income countries seeking to prevent pregnancy are not using modern contraception, according to the World Health Organization, and nearly 40 percent of women who start using shorter-acting contraception stop within the first year because they are unfamiliar with the methods. available methods. The foundation notes that efforts to develop new birth control technologies are chronically underfunded.

About Insilico Medicine

Insilico Medicine, an end-to-end artificial intelligence (AI) powered clinical stage drug discovery company, connects biology, chemistry and clinical trial analysis using next generation AI systems. The company has developed AI platforms that use deep generative models, reinforcement learning, transformers and other modern machine learning techniques to discover new targets and generate new molecular structures with desirable properties. Insilico Medicine develops breakthrough solutions for the discovery and development of innovative medicines for cancer, fibrosis, immunity, diseases of the central nervous system, infectious diseases, autoimmune diseases and aging-related diseases.

Must Read
AI model predicts survival in idiopathic pulmonary fibrosis patients

Website: www.insilico.com

Contact: media@insilico.com

        
RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Recent Comments